Amyloid β-but not Tau-induced neurotoxicity is suppressed by Manuka honey via HSP-16.2 and SKN-1/Nrf2 pathways in an in vivo model of Alzheimer’s disease
Metadatos
Mostrar el registro completo del ítemAutor
Navarro Hortal, María Dolores; Romero Márquez, José Manuel; Muñoz Ollero, Pedro; Jiménez Trigo, Victoria; Esteban Muñoz, Adelaida; Sánchez González, Cristina; Rivas García, Lorenzo; Llopis González, Juan; Forbes Hernández, Tamara Yuliett; Quiles Morales, José LuisEditorial
Royal Society of Chemistry
Fecha
2022-10-07Referencia bibliográfica
Food Funct., 2022, 13, 11185. DOI: [10.1039/d2fo01739c]
Patrocinador
MCIN/AEI FPU2017/04358; FSE "El FSE invierte en tu futuro" FPU2018/05301; JdC-I post-doctoral contract - NextGenerationEU IJC2020-043910-I; FEDER/Junta de Andalucia-Consejeria de Economia y Conocimiento B-AGR-193-UGR18Resumen
Alzheimer’s is a chronic degenerative disease of the central nervous system considered the leading cause
of dementia in the world. It is characterized by two etiopathological events related to oxidative stress: the
aggregation of β-amyloid peptide and the formation of neurofibrillary tangles of hyperphosphorylated
Tau protein in the brain. The incidence of this disease increases with age and has been associated with
inadequate lifestyles. Some natural compounds have been shown to improve the hallmarks of the disease.
However, despite its potential, there is no scientific evidence about Manuka honey (MH) in this regard. In
the present work we evaluated the effect of MH on the toxicity induced by Aβ aggregation and Tau in a
Caenorhabditis elegans model. Our results demonstrated that MH was able to improve indicators of oxidative
stress and delayed Aβ-induced paralysis in the AD model CL4176 through HSP-16.2 and SKN-1/
NRF2 pathways. Nevertheless, its sugar content impaired the indicators of locomotion (an indicator of tau
neurotoxicity) in both the transgenic strain BR5706 and in the wild-type N2 worms.